Dataset Information

Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.

ABSTRACT:

Background

Pharmacodynamic biomarkers are becoming increasingly valuable for assessing drug activity and target modulation in clinical trials. However, identifying quality biomarkers is challenging due to the increasing volume and heterogeneity of relevant data describing the biological networks that underlie disease mechanisms. A biological pathway network typically includes entities (e.g. genes, proteins and chemicals/drugs) as well as the relationships between these and is typically curated or mined from structured databases and textual co-occurrence data. We propose a hybrid Natural Language Processing and directed relationships-based network analysis approach using IBM Watson for Drug Discovery to rank all human genes and identify potential candidate biomarkers, requiring only an initial determination of a specific target-disease relationship.

Methods

Through natural language processing of scientific literature, Watson for Drug Discovery creates a network of semantic relationships between biological concepts such as genes, drugs, and diseases. Using Bruton's tyrosine kinase as a case study, Watson for Drug Discovery's automatically extracted relationship network was compared with a prominent manually curated physical interaction network. Additionally, potential biomarkers for Bruton's tyrosine kinase inhibition were predicted using a matrix factorization approach and subsequently compared with expert-generated biomarkers.

Results

Watson's natural language processing generated a relationship network matching 55 (86%) genes upstream of BTK and 98 (95%) genes downstream of Bruton's tyrosine kinase in a prominent manually curated physical interaction network. Matrix factorization analysis predicted 11 of 13 genes identified by Merck subject matter experts in the top 20% of Watson for Drug Discovery's 13,595 ranked genes, with 7 in the top 5%.

Conclusion

Taken together, these results suggest that Watson for Drug Discovery's automatic relationship network identifies the majority of upstream and downstream genes in biological pathway networks and can be used to help with the identification and prioritization of pharmacodynamic biomarker evaluation, accelerating the early phases of disease hypothesis generation.

SUBMITTER: Hatz S

PROVIDER: S-EPMC6453528 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.

Hatz Sonja S Spangler Scott S Bender Andrew A Studham Matthew M Haselmayer Philipp P Lacoste Alix M B AMB Willis Van C VC Martin Richard L RL Gurulingappa Harsha H Betz Ulrich U

PloS one 20190408 4

<h4>Background</h4>Pharmacodynamic biomarkers are becoming increasingly valuable for assessing drug activity and target modulation in clinical trials. However, identifying quality biomarkers is challenging due to the increasing volume and heterogeneity of relevant data describing the biological networks that underlie disease mechanisms. A biological pathway network typically includes entities (e.g. genes, proteins and chemicals/drugs) as well as the relationships between these and is typically c ...[more]

PMID: 30958864

Similar Datasets

Project description:BACKGROUND:Text mining (TM) methods have been used extensively to extract relations and events from the literature. In addition, TM techniques have been used to extract various types or dimensions of interpretative information, known as Meta-Knowledge (MK), from the context of relations and events, e.g. negation, speculation, certainty and knowledge type. However, most existing methods have focussed on the extraction of individual dimensions of MK, without investigating how they can be combined to obtain even richer contextual information. In this paper, we describe a novel, supervised method to extract new MK dimensions that encode Research Hypotheses (an author's intended knowledge gain) and New Knowledge (an author's findings). The method incorporates various features, including a combination of simple MK dimensions. METHODS:We identify previously explored dimensions and then use a random forest to combine these with linguistic features into a classification model. To facilitate evaluation of the model, we have enriched two existing corpora annotated with relations and events, i.e., a subset of the GENIA-MK corpus and the EU-ADR corpus, by adding attributes to encode whether each relation or event corresponds to Research Hypothesis or New Knowledge. In the GENIA-MK corpus, these new attributes complement simpler MK dimensions that had previously been annotated. RESULTS:We show that our approach is able to assign different types of MK dimensions to relations and events with a high degree of accuracy. Firstly, our method is able to improve upon the previously reported state of the art performance for an existing dimension, i.e., Knowledge Type. Secondly, we also demonstrate high F1-score in predicting the new dimensions of Research Hypothesis (GENIA: 0.914, EU-ADR 0.802) and New Knowledge (GENIA: 0.829, EU-ADR 0.836). CONCLUSION:We have presented a novel approach for predicting New Knowledge and Research Hypothesis, which combines simple MK dimensions to achieve high F1-scores. The extraction of such information is valuable for a number of practical TM applications.

Project description:BackgroundIBM Watson for Oncology (WFO), which can use natural language processing to evaluate data in structured and unstructured formats, has begun to be used in China. It provides physicians with evidence-based treatment options and ranks them in three categories for treatment decision support. This study was designed to examine the concordance between the treatment recommendation proposed by WFO and actual clinical decisions by oncologists in our cancer center, which would reflect the differences of cancer treatment between China and the U.S.Patients and methodsRetrospective data from 362 patients with cancer were ingested into WFO from April 2017 to October 2017. WFO recommendations were provided in three categories: recommended, for consideration, and not recommended. Concordance was analyzed by comparing the treatment decisions proposed by WFO with those of the multidisciplinary tumor board. Concordance was achieved when the oncologists' treatment decisions were in the recommended or for consideration categories in WFO.ResultsOvarian cancer showed the highest concordance, which was 96%. Lung cancer and breast cancer obtained a concordance of slightly above 80%. The concordance of rectal cancer was 74%, whereas colon cancer and cervical cancer showed the same concordance of 64%. In particular, the concordance of gastric cancer was very low, only 12%, and 88% of cases were under physicians choice.ConclusionDifferent cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major cause of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. ClinicalTrials.gov Identifier: NCT03400514.Implications for practiceIBM Watson for Oncology (WFO) has begun to be used in China. In this study, concordance was examined between the treatment recommendation proposed by WFO and clinical decisions for 362 patients in our cancer center, which could reflect the differences of cancer treatment between China and the U.S. Different cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major causes of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. This study may have a significant effect on application of artificial intelligence systems in China.

Project description:Gastric cancer (GC) is one of the most common malignant tumors and ranks third in cancer mortality globally. Although, a lot of advancements have been made in diagnosis and treatment of gastric cancer, there is still lack of ideal biomarker for the diagnosis and treatment of gastric cancer. Due to the poor prognosis, the survival rate is not improved much. Circular RNAs (circRNAs) are single-stranded RNAs with a covalently closed loop structure that don't have the 5'-3' polarity and a 3' polyA tail. Because of their circular structure, circRNAs are more stable than linear RNAs. Previous studies have found that circRNAs are involved in several biological processes like cell cycle, proliferation, apoptosis, autophagy, migration and invasion in different cancers, and participate in some molecular mechanisms including sponging microRNAs (miRNAs), protein translation and binding to RNA-binding proteins. Several studies have reported that circRNAs play crucial role in the occurrence and development of different types of cancers. Although, some studies have reported several circRNAs in gastric cancer, more studies are needed in searching new biomarkers for gastric cancer diagnosis and treatment. Here, we investigated potential circRNA biomarkers for GC using next-generation sequencing (NGS) data collected from 5 paired GC samples. A total of 45,783 circRNAs were identified in all samples and among them 478 were differentially expressed (DE). The gene ontology (GO) analysis of the host genes of the DE circRNAs showed that some genes were enriched in several important biological processes, molecular functions and cellular components. The Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis revealed that some host genes were enriched in several GC related pathways. The circRNA-miRNA-gene interaction network analysis showed that two circRNAs circCEACAM5 and circCOL1A1 were interacted with gastric cancer related miRNAs, and their host genes were also the important therapeutic and prognostic biomarkers for GC. The experimental results also validated that these two circRNAs were DE in GC compared to adjacent normal tissues. Overall, our findings suggest that these two circRNAs circCEACAM5 and circCOL1A1 might be the potential biomarkers for the diagnosis and treatment of GC.

Dataset Information

Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.

Background

Methods

Results

Conclusion

Publications

Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets